Corbus Pharmaceuticals Holdings, Inc.

NASDAQ:CRBP

Biotechnology

Healthcare
$2.44 +1.73%

+$0.14 today

Market cap
$50.18M
Beta
2.59
P/E (TTM)
-1.3
EPS (TTM)
-$6.35
52W Low $6.72High $20.56

Volume 0.66M

Average 0.42M

Returns on capital

Corbus Pharmaceuticals Holdings, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-53.2%

avg -150.7%

ROIC

-57.2%

avg -160.0%

ROA

-46.7%

avg -87.1%

Analysis

ROA is currently the strongest return metric at -46.7% versus its period average of -87.1%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Yuval Cohen

Chief Executive Officer & DirectorUSD 1.04M51157.32K1.25%

Leonardo Viana Nicacio

Chief Medical OfficerUSD 720.99K4858.33K0.47%

Sean F. Moran

Chief Financial OfficerUSD 695.75K6884.69K0.68%

Ian Hodgson

Chief Operating Officer—5351.08K0.41%

G. Scott Goeken

General Counsel & Corporate Secretary————

Nishant C. Saxena

Chief Business Officer——77.90K0.62%

Christina Bertsch

Vice President of Human Resources————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Aug 16, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

3

$126,254.94

Sells

14

$2.72M

Net Transaction Value

−$2.59M

Net selling

Most Active

Saxena Nishant C

3 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Oct 29, 26

Cormorant Asset Management, LP

Indirect

Sell$1.7M
Sep 14, 26

Ben Yong

Direct

Sell$15.7K
Aug 11, 26

Saxena Nishant C

Direct

Buy$25K
Aug 7, 26

Cohen Yuval

Direct

Sell$171.4K
Aug 7, 26

Moran Sean F.

Direct

Sell$121K
Jun 10, 26

Kung Winston

Direct

Sell$16K
Jun 10, 26

Altmeyer Anne

Direct

Sell$19.1K
Jun 10, 26

Jenkins John Kenneth

Direct

Sell$38K
Jun 3, 26

Saxena Nishant C

Direct

Buy$68.2K
Jun 2, 26

Saxena Nishant C

Direct

Buy$33K

1–10 of 17

Summary

Insiders reported 3 buys worth $126,254.94 and 14 sells worth $2.72M over the last 12 months. That adds up to net selling of $2.59M. Saxena Nishant C was the most active insider with 3 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A5 analysts
RevenueN/AN/AN/A
N/A4 analysts
Net IncomeN/AN/AN/A
N/A4 analysts
EBITN/AN/AN/A
N/A4 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does Corbus Pharmaceuticals Holdings, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about CRBP's management, answered from reported figures.

Who manages CRBP?

Corbus Pharmaceuticals Holdings, Inc. (CRBP) lists 7 active executives. The top listed executive is Leonardo Viana Nicacio, Chief Medical Officer.

Are CRBP insiders buying or selling?

Recent insider activity shows net buying of $67.67M.